Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2238-2246

  Qin, Bin ^a   Dong, Lei ^a   Guo, Xiaoyan ^a   Jiang, Jiong ^a   He, Yangxin ^a   Wang, Xiaoyan ^a   Li, Lu ^a   Zhao, Juhui ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Estrogen; Estrogen receptor; G protein coupled estrogen receptor; GPER; Irritable bowel syndrome

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; GENETIC MARKER; GPER PROTEIN, HUMAN; MESSENGER RNA;

ABDOMINAL PAIN; ADULT; BIOPSY; CASE CONTROL STUDY; CHEMISTRY; COLON; COLONOSCOPY; CONSTIPATION; DIARRHEA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC MARKER; GENETICS; HUMAN; INTESTINE MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; METABOLISM; MIDDLE AGED; PAIN MEASUREMENT; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ABDOMINAL PAIN; ADULT; BIOPSY; CASE-CONTROL STUDIES; COLON; COLONOSCOPY; CONSTIPATION; DIARRHEA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC MARKERS; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84902436513     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cain KC, Jarrett ME, Burr RL, Rosen S, Hertig VL and Heitkemper MM. Gender differences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome. Dig Dis Sci 2009; 54: 1542-1549.
2. Chang FY, Lu CL and Chen TS. The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil 2010; 16: 389-400.
3. Anbardan SJ, Daryani NE, Fereshtehnejad SM, Taba Taba Vakili S, Keramati MR and Ajdarkosh H. Gender Role in Irritable Bowel Syndrome: A comparison of irritable bowel syndrome module (ROME III) between male and female patients. J Neurogastroenterol Motil 2012; 18: 70-77.
4. Jane ZY, Chang CC, Lin HK, Liu YC and Chen WL. The association between the exacerbation of irritable bowel syndrome and menstrual symptoms in young Taiwanese women. Gastroenterol Nurs 2011; 34: 277-286.
5. Kane SV, Sable K and Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 1998; 93: 1867-1872.
6. Houghton LA, Lea R, Jackson N and Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471-474.
7. Ouyang A and Wrzos HF. Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? Am J Gastroenterol 2006; 101: S602-609.
8. Chaloner A and Greenwood-Van Meerveld B. Sexually dimorphic effects of unpredictable early life adversity on visceral pain behavior in a rodent model. J Pain 2013; 14: 270-280.
9. Sanoja R and Cervero F. Estrogen-dependent abdominal hyperalgesia induced by ovariectomy in adult mice: a model of functional abdominal pain. Pain 2005; 118: 243-253.
10. Cao DY, Ji Y, Tang B and Traub RJ. Estrogen receptor beta activation is antinociceptive in a model of visceral pain in the rat. J Pain 2012; 13: 685-694.
11. Welboren WJ, Sweep FC, Span PN and Stunnenberg HG. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009; 16: 1073-1089.
12. Rouayrenc JF, Vignon F, Bringer J and Pujol P. [Non-genomic steroid effects: estrogen action revisited]. Ann Endocrinol (Paris) 2000; 61: 517-523.
13. Carmeci C, Thompson DA, Ring HZ, Francke U and Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997; 45: 607-617.
14. Kvingedal AM and Smeland EB. A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett 1997; 407: 59-62.
15. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA and Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
16. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A and O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457.
17. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A and Hebuterne X. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473.
18. Kim MS, Chae HJ, Shin TY, Kim HM and Kim HR. Estrogen regulates cytokine release in human mast cells. Immunopharmacol Immunotoxicol 2001; 23: 495-504.
19. Zaitsu M, Narita S, Lambert KC, Grady JJ, Estes DM, Curran EM, Brooks EG, Watson CS, Goldblum RM and Midoro-Horiuti T. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol 2007; 44: 1977-1985.
20. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP and Neunlist M. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
21. Wilcz-Villega E, McClean S and O'Sullivan M. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. Neurogastroenterol Motil 2014; 26: 316-25.
22. Tang B, Ji Y and Traub RJ. Estrogen alters spinal NMDA receptor activity via a PKA signaling pathway in a visceral pain model in the rat. Pain 2008; 137: 540-549.
23. Moussa L, Bezirard V, Salvador-Cartier C, Bacquie V, Houdeau E and Theodorou V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin Nutr 2013; 32: 51-58.
24. Revankar CM, Cimino DF, Sklar LA, Arterburn JB and Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
25. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ and Brailoiu E. Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception. J Pain 2012; 13: 742-754.
26. Lu CL, Hsieh JC, Dun NJ, Oprea TI, Wang PS, Luo JC, Lin HC, Chang FY and Lee SD. Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 2009; 137: 1040-1050.
27. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R and Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
28. Larauche M. Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity. Neurogastroenterol Motil 2012; 24: 201-205.
29. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM and Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-1221.
30. Zierau O, Zenclussen AC and Jensen F. Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol 2012; 3: 169.